WO2003004529A3 - Ephrin-tie receptor materials and methods - Google Patents

Ephrin-tie receptor materials and methods Download PDF

Info

Publication number
WO2003004529A3
WO2003004529A3 PCT/IB2002/002524 IB0202524W WO03004529A3 WO 2003004529 A3 WO2003004529 A3 WO 2003004529A3 IB 0202524 W IB0202524 W IB 0202524W WO 03004529 A3 WO03004529 A3 WO 03004529A3
Authority
WO
WIPO (PCT)
Prior art keywords
ephrin
methods
tie receptor
receptor materials
materials
Prior art date
Application number
PCT/IB2002/002524
Other languages
French (fr)
Other versions
WO2003004529A2 (en
Inventor
Kari Alitalo
Hajime Kubo
Original Assignee
Licentia Ltd
Kari Alitalo
Hajime Kubo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US30296001P priority Critical
Priority to US60/302,960 priority
Application filed by Licentia Ltd, Kari Alitalo, Hajime Kubo filed Critical Licentia Ltd
Publication of WO2003004529A2 publication Critical patent/WO2003004529A2/en
Publication of WO2003004529A3 publication Critical patent/WO2003004529A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Abstract

The present invention provides materials and methods relating to the interaction between Tie receptors and Ephrin polypeptides.
PCT/IB2002/002524 2001-07-02 2002-07-02 Ephrin-tie receptor materials and methods WO2003004529A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US30296001P true 2001-07-02 2001-07-02
US60/302,960 2001-07-02

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2002314433A AU2002314433A1 (en) 2001-07-02 2002-07-02 Ephrin-tie receptor materials and methods

Publications (2)

Publication Number Publication Date
WO2003004529A2 WO2003004529A2 (en) 2003-01-16
WO2003004529A3 true WO2003004529A3 (en) 2004-06-10

Family

ID=23169976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002524 WO2003004529A2 (en) 2001-07-02 2002-07-02 Ephrin-tie receptor materials and methods

Country Status (2)

Country Link
AU (1) AU2002314433A1 (en)
WO (1) WO2003004529A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10695433B2 (en) 2013-10-11 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466333A1 (en) * 2001-11-09 2003-05-15 Neuronova Ab Method of proliferation in neurogenic regions
GB0208089D0 (en) 2002-04-09 2002-05-22 Oxford Glycosciences Uk Ltd Protein
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
ES2669510T3 (en) 2004-09-23 2018-05-28 Genentech, Inc. Antibodies and conjugates engineered with cysteine
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
JP5972864B2 (en) 2010-04-15 2016-08-17 メディミューン リミテッド Pyrrolobenzodiazepines and their conjugates
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
SI2906253T1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
DK2839860T3 (en) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
MX364329B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates.
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
PT2906251T (en) 2012-10-12 2017-12-04 Medimmune Ltd Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
EP2968596B1 (en) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105209077B (en) 2013-03-13 2019-06-11 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TWI636792B (en) 2013-08-12 2018-10-01 建南德克公司 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
KR20160092024A (en) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3082874A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082875A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
EP3388449A3 (en) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
BR112017005393A2 (en) 2014-09-17 2017-12-05 Genentech Inc compound of formula I, method of preparing a conjugate of formula a, conjugate of formula a1, composition comprising a mixture of antibody-drug conjugate compounds, pharmaceutical composition, and use of a conjugate or composition
KR20170086121A (en) 2014-12-03 2017-07-25 제넨테크, 인크. Quaternary amine compounds and antibody-drug conjugates thereof
PE20181067A1 (en) 2015-10-02 2018-07-04 Genentech Inc Conjugates pirrolobenzodiazepina antibody-drug and methods of use
CN108472384A (en) 2015-10-16 2018-08-31 基因泰克公司 Be obstructed disulphide drug conjugate
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
EP3433621A1 (en) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック, インコーポレイテッド PROTAC antibody conjugates and methods of use
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
CN109476648A (en) 2016-06-06 2019-03-15 豪夫迈·罗氏有限公司 Si Weisi groups of antibody-drug conjugates and application method
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP2019537558A (en) 2016-10-05 2019-12-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Preparation method of antibody drug conjugate
AU2018253948A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
CA3074688A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030673A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
WO2001012840A2 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Anti-epha2 antibodies as a cancer diagnostic
WO2001097850A2 (en) * 2000-06-23 2001-12-27 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030673A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
WO2001012840A2 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Anti-epha2 antibodies as a cancer diagnostic
WO2001097850A2 (en) * 2000-06-23 2001-12-27 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10695433B2 (en) 2013-10-11 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates

Also Published As

Publication number Publication date
AU2002314433A1 (en) 2003-01-21
WO2003004529A2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
EG22902A (en) Composite materials
DK1379239T3 (en) N (2-aryl-ethyl) -benzylamines as antagonists of the HT6 receptor
GB2374086B (en) Composite sliding material
DE69932832D1 (en) Receptor based antagonists and method for the production and use thereof
HK1131744A1 (en) Toll like receptor 3 antagonists, methods and uses toll
HK1095534A1 (en) Pharmaceutical preparation containing an antibody against the egf receptor
PL211250B1 (en) 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
PL370163A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
DE60215000D1 (en) DIHYDROPYRROLOi1,2-AöINDOL AND TETRAHYDROPYRIDOi1,2-AOXINDOLE DERIVATIVES AS PROSTAGLANDIN RECEPTOR ANTAGONISTS
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
AU2002326920A1 (en) Semiconductor nanocrystal composite
DE50212615D1 (en) Lyophilized preparation containing antibodies against the EGF receptor
AU2001293847A1 (en) Metabotropic glutamate receptor antagonists
AU2002308782A1 (en) Tensegrity unit, structure and method for construction
AT354570T (en) 5,6-diaryl-pyrazineamide derivatives as cb1 antagonists
DE60228406D1 (en) Pyrazoloe3,4-dypyrimidine derivatives and their use as antagonists of the purinergen receptor
RU2005110061A (en) Substituted piperasines, (1,4) -diazepines and 2,5-diazabicyclo (2,2,1) heptanes as h1-and / or h3-histamin antagonists or h3 histamin reverse antagonists
AU2002322477A1 (en) Composite binding polypeptides
MXPA03008715A (en) Reducing the immunogenicity of fusion proteins.
HRP20031042A2 (en) 5-ht receptor ligands and uses thereof
DE69929019D1 (en) Mu-1, a member of the cytokin receptor family
MXPA02004985A (en) Npyy5 antagonists.
SI1309691T1 (en) Anti-tnf antibodies, compositions, methods and uses
MXPA03002263A (en) Substituted urea neuropeptide y y5 receptor antagonists.
MY128427A (en) Construction material

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP